-
1st SCD Trial Patient Shows CTX001 Gene Editing to be Safe, Effective
CTX001 boosted fetal hemoglobin levels and prevented vaso-occlusive crises in the first tested patient with severe sickle cell disease, early data show. Click here to learn more.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.